ARTICLE

KLBF - A IDR1.07 tn net profit in 1Q25 Kalbe Fama (KLBF) reported a 12.43% yoy increase in net profit to IDR1.07 tn in 1Q25 and a 5.76% yoy rise in net sales to IDR8.84 tn with improved gross margin at 41.6%. The growth was fueled by solid performance across prescription drugs, health products, and logistics, along with effective cost control and favorable product mix. KLBF continues to focus on expanding its oncology, biologic, and generic drug ecosystem, developing affordable nutrition products, and strengthening distribution through medical device initiatives, while maintaining a selective pricing strategy and digital efficiency to sustain margins. (Source: Bisnis Indonesia)